These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37722510)

  • 1. Comparison of three DREADD agonists acting on Gq-DREADDs in the ventral tegmental area to alter locomotor activity in tyrosine hydroxylase:Cre male and female rats.
    Robinson HL; Nicholson KL; Shelton KL; Hamilton PJ; Banks ML
    Behav Brain Res; 2023 Oct; 455():114674. PubMed ID: 37722510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
    Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
    Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of DREADD agonists and administration route in a murine model of sleep enhancement.
    Ferrari LL; Ogbeide-Latario OE; Gompf HS; Anaclet C
    J Neurosci Methods; 2022 Oct; 380():109679. PubMed ID: 35914577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and slice electrophysiological assessment of DREADD ligand, deschloroclozapine (DCZ) in rats.
    Nentwig TB; Obray JD; Vaughan DT; Chandler LJ
    Sci Rep; 2022 Apr; 12(1):6595. PubMed ID: 35449195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.
    Lawson KA; Ruiz CM; Mahler SV
    Psychopharmacology (Berl); 2023 Oct; 240(10):2101-2110. PubMed ID: 37530882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
    Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
    Elife; 2023 Mar; 12():. PubMed ID: 36892930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated chemogenetic activation of dopaminergic neurons induces reversible changes in baseline and amphetamine-induced behaviors.
    Chohan MO; Fein H; Mirro S; O'Reilly KC; Veenstra-VanderWeele J
    Psychopharmacology (Berl); 2023 Dec; 240(12):2545-2560. PubMed ID: 37594501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
    MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
    eNeuro; 2016; 3(5):. PubMed ID: 27822508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventral Tegmental Area Dopamine Cell Activation during Male Rat Sexual Behavior Regulates Neuroplasticity and d-Amphetamine Cross-Sensitization following Sex Abstinence.
    Beloate LN; Omrani A; Adan RA; Webb IC; Coolen LM
    J Neurosci; 2016 Sep; 36(38):9949-61. PubMed ID: 27656032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.
    Lawson KA; Ruiz CM; Mahler SV
    bioRxiv; 2023 Mar; ():. PubMed ID: 37034819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent reduction in cocaine-induced locomotion by Clozapine-N-Oxide in rats with a history of cocaine self-administration.
    Padovan-Hernandez Y; Knackstedt LA
    Neurosci Lett; 2018 May; 674():132-135. PubMed ID: 29571824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A novel ligand for chemogenetic receptors, Deschloroclozapine, enables rapid and selective modulation of neuronal activity and behavior in living animals].
    Nagai Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):233-237. PubMed ID: 35781451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities in the composition of the gut microbiota in mice after repeated administration of DREADD ligands.
    Guo W; Wan X; Ma L; Zhang J; Hashimoto K
    Brain Res Bull; 2021 Aug; 173():66-73. PubMed ID: 34004259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
    Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
    J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G
    Marciante AB; Farmer GE; Cunningham JT
    J Neurophysiol; 2020 Aug; 124(2):591-609. PubMed ID: 32697679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deschloroclozapine exhibits an exquisite agonistic effect at lower concentration compared to clozapine-N-oxide in hM3Dq expressing chemogenetically modified rats.
    Shimizu M; Yoshimura M; Baba K; Ikeda N; Nonaka Y; Maruyama T; Onaka T; Ueta Y
    Front Neurosci; 2023; 17():1301515. PubMed ID: 38099201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.
    Manvich DF; Webster KA; Foster SL; Farrell MS; Ritchie JC; Porter JH; Weinshenker D
    Sci Rep; 2018 Mar; 8(1):3840. PubMed ID: 29497149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
    Nagai Y; Miyakawa N; Takuwa H; Hori Y; Oyama K; Ji B; Takahashi M; Huang XP; Slocum ST; DiBerto JF; Xiong Y; Urushihata T; Hirabayashi T; Fujimoto A; Mimura K; English JG; Liu J; Inoue KI; Kumata K; Seki C; Ono M; Shimojo M; Zhang MR; Tomita Y; Nakahara J; Suhara T; Takada M; Higuchi M; Jin J; Roth BL; Minamimoto T
    Nat Neurosci; 2020 Sep; 23(9):1157-1167. PubMed ID: 32632286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-examining the role of ventral tegmental area dopaminergic neurons in motor activity and reinforcement by chemogenetic and optogenetic manipulation in mice.
    Jing MY; Han X; Zhao TY; Wang ZY; Lu GY; Wu N; Song R; Li J
    Metab Brain Dis; 2019 Oct; 34(5):1421-1430. PubMed ID: 31313126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization to amphetamine psychostimulant effect: A key role for ventral tegmental area neurotensin type 2 receptors and MAP kinase pathway.
    Voyer D; Einsiedel J; Gmeiner P; Lévesque D; Rompré PP
    Addict Biol; 2021 Sep; 26(5):e13008. PubMed ID: 33491227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.